Boehringer: FDA approves Cyltezo® Pen autoinjector

  Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the Cyltezo^® Pen, a new autoinjector option for Cyltezo (adalimumab-adbm), an FDA-approved Interchangeable biosimilar to Humira^® (adalimumab). Initially approved as a pre-filled syringe, Cyltezo is indicated to treat multiple chronic inflammatory diseases. The 40 mg/0.8 mL pre-filled Cyltezo Pen will be available in two-, four- and six-pack options on July 1, 2023.

https://www.biospace.com/article/releases/us-fda-approves-the-cyltezo-pen-a-new-autoinjector-option-ahead-of-july-1-commercial-launch/